• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Eisai Co. Ltd (OP: ESALF )

    40.00 -3.85 (-8.78%)
    Streaming Delayed Price Updated: 2:26 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 146
    Open 40.00
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 43.85
    Today's Range 40.00 - 40.00
    52wk Range 37.53 - 65.72
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
    Via Benzinga
    Topics Bankruptcy
    Exposures Financial Legal
    Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
    The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    -19.40%
    -19.40%
    1 Month
    N/A
    N/A
    3 Month
    +3.33%
    +3.33%
    6 Month
    -13.89%
    -13.89%
    1 Year
    -38.59%
    -38.59%

    More News

    Read More
    Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
    Via Benzinga
    Exposures Product Safety
    European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
    Via Benzinga
    Current Analysis: Eisai Co Ltd (ESAIY)
    Via Talk Markets
    Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
    Via Benzinga
    Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
    Via Benzinga
    LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly
    Via Benzinga
    Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories
    Via Benzinga
    Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
    Via Benzinga
    Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
    Via Benzinga
    Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial
    Via Benzinga
    Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
    Via Benzinga
    Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
    Via Benzinga
    Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
    Via Benzinga
    Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
    Via Benzinga
    FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
    Via Benzinga
    Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
    Via Benzinga
    Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
    Via Benzinga
    Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
    Via Benzinga
    National Institute on Aging Aims Building $300M Alzheimer's Research Database
    Via Benzinga
    Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
    Via Benzinga
    Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
    Via Benzinga
    Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
    Via Benzinga
    Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.